# US 2023/0404924 A1 · Modified release formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404924 A1
- Document ID: US20230404924A1
- Status: Published application
- Kind: A1
- Application number: 18/118,479
- Filed: 2023-03-07
- Published: 2023-12-21
- Earliest claimed: 2019-06-04
- Assignees: Sunovion Pharmaceuticals Inc.
- Applicants: Sunovion Pharmaceuticals Inc.
- Inventors: Takumi Asada; Gerald R. Galluppi; Seth Cabot Hopkins; Megumi Maruyama; Siriporn Toongsuwan; Yuki Tsushima
- Web page: https://patentgrep.com/patent/US20230404924A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

## Claims

### Claim at position 1

1-116. (canceled)

### Claim 117

A solid dosage form composition comprising from about 100 to about 600 mg of a non-racemic mixture of amisulpride by weight of the free base, comprising:
(R)-(+)-amisulpride or a pharmaceutically acceptable salt thereof and (S)-(−)-amisulpride or a pharmaceutically acceptable salt thereof at an enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−)-amisulpride that is from about 65:35 to about 88:12 by weight of the free base;
an extended-release agent in an amount between about 10% to about 50% by weight of the total solid oral dosage form weight to provide a modified-release dosage form;
wherein the solid dosage form using an in vitro gastrointestinal simulation test releases less than about 30% of amisulpride after about 1 hour, releases more than about 20% and less than about 60% of amisulpride after about 3 hours, and releases more than about 30% and less than about 100% of amisulpride mixture after about 6 hours.

### Claim 118 (depends on 117)

The solid dosage form composition of claim 117, wherein the in vitro gastrointestinal simulation test is a two-stage gastrointestinal simulation dissolution test comprising in the first stage 500 ml of an aqueous media having a pH of about 2 and adding after 1 hour 400 ml of an aqueous buffer media such that the second stage pH is 6.8; where the temperature in both stages of the two-stage in vitro gastrointestinal simulation dissolution test is about 37° C.

### Claim 119 (depends on 117)

The solid dosage form composition of claim 117, wherein the in vitro gastrointestinal simulation test is a two-stage gastrointestinal simulation dissolution test conducted in a paddle apparatus substantially in accord with that described in one of more of: (a) United States Pharmacopeia Convention (USP) Apparatus 2 of Chapter 711 Dissolution; USP41-NF36 General Chapter <711> Dissolution, and (b) Japanese Pharmacopeia (JP) General test <6.10>.

### Claim 120 (depends on 117)

The solid dosage form composition of claim 117, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases less than about 30% of amisulpride after about 1 hour, releases more than about 20% and less than about 60% of amisulpride after about 3 hours, and releases more than about 30% and less than about 75% of amisulpride after about 6 hours.

### Claim 121 (depends on 117)

The solid dosage form composition of claim 117, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases less than about 20% of amisulpride after about 1 hour, releases more than about 20% and less than about 50% of amisulpride after about 3 hours, and releases more than about 30% and less than about 75% of amisulpride after about 6 hours.

### Claim 122 (depends on 117)

The solid dosage form composition of claim 117, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases more than about 30% and less than about 50% of amisulpride after about 6 hours.

### Claim 123 (depends on 117)

The solid dosage form composition of claim 117, wherein the non-racemic mixture of amisulpride comprises (R)-(+)-amisulpride or a pharmaceutically acceptable salt thereof and (S)-(−)-amisulpride or a pharmaceutically acceptable salt thereof at an enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−)-amisulpride that is about 75:25 to about 88:12 by weight of free base.

### Claim 124 (depends on 117)

The solid dosage form composition of claim 117, wherein the non-racemic mixture of amisulpride comprises (R)-(+)-amisulpride or a pharmaceutically acceptable salt thereof and (S)-(−)-amisulpride or a pharmaceutically acceptable salt thereof at an enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−)-amisulpride that is about 80:20 to about 88:12 by weight of free base.

### Claim 125 (depends on 117)

The solid dosage form composition of claim 117, wherein the non-racemic mixture of amisulpride compromises (R)-(+)-amisulpride or a pharmaceutically acceptable salt thereof and (S)-(−)-amisulpride or a pharmaceutically acceptable salt thereof at an enantiomeric ratio of (R)-(+)-amisulpride to (S)-(−)-amisulpride that is about 85:15 by weight of the free base.

### Claim 126 (depends on 125)

The solid dosage form composition of claim 125, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases no more than about 30% of amisulpride after about 1 hour, releases between about 30% and about 75% of amisulpride after about 3 hours, and releases more than about 75% of amisulpride after about 12 hours.

### Claim 127 (depends on 125)

The solid dosage form composition of claim 125, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases after 30 minutes between about 6% and about 43% of the amisulpride, releases after 2 hours between about 18% and about 96% of the amisulpride, and after 6 hours releases between about 44% and about 98% of the amisulpride.

### Claim 128 (depends on 125)

The solid dosage form composition of claim 125, wherein the solid dosage form in a two-stage dissolution in vitro gastrointestinal simulation test releases between about 10% and about 22% of the amisulpride at 30 minutes, about 27% and about 92% of the amisulpride at 2 hours, and between about 43% and 98% of the amisulpride at 6 hours.

### Claim 129 (depends on 117)

The solid dosage form composition of claim 117, wherein said solid oral dosage composition is a tablet.

### Claim 130 (depends on 117)

The solid dosage form composition of claim 117, wherein the extended release agent comprises a matrix forming agent.

### Claim 131 (depends on 130)

The solid dosage form composition of claim 130, wherein the matrix forming agent comprises one or more cellulosic ethers.

### Claim 132 (depends on 130)

The solid dosage form composition of claim 130, wherein the matrix forming agent comprises one or more cellulosic ethers, polymer coatings, polymer matrix systems, enzyme-activated systems, pH independent polymers, or pH dependent polymers.

### Claim 133 (depends on 117)

The solid dosage form composition of claim 117, wherein the extended release agent comprises one or more alginate material, carboxyvinyl polymer, sodium salts of carboxymethyl cellulose, propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, methyl cellulose, xanthan gum, polyethylene oxide, ammonio methacrylate copolymers type A and B as described in USP, polyacrylate dispersion 30% as described in Ph. Eur., or hydroxypropyl methylcellulose.

### Claim 134 (depends on 117)

The solid dosage form composition of claim 117, wherein the extended release agent comprises one or more hydroxypropylcellulose or hydroxypropyl methylcellulose.

### Claim 135 (depends on 117)

The solid dosage form composition of claim 117, wherein the extended release agent is in an amount between about 20% to about 40% by total solid oral dosage composition weight.

### Claim 136 (depends on 134)

The solid dosage form composition of claim 134, wherein the extended release agent comprises hydroxypropyl methylcellulose in an amount between about 20% to about 40% by total solid oral dosage composition weight.

### Claim 137 (depends on 134)

The solid dosage form composition of claim 134, wherein the extended release agent comprises hydroxypropyl methylcellulose in an amount between about 20% to about 30% by total solid oral dosage composition weight.

### Claim 138 (depends on 134)

The solid dosage form composition of claim 134, wherein the extended release agent comprises hydroxypropyl methylcellulose in an amount of about 25% by total solid oral dosage composition weight.

### Claim 139 (depends on 117)

The solid dosage form composition of claim 117, which provides a population Cmax/Cmin ratio of amisulpride that is less than about 2, wherein the values of Cmax and Cmin are determined within 9 hours after administration.

### Claim 140 (depends on 117)

The solid dosage form composition of claim 117, wherein after administration to a subject provides a Cmax that is less than 75% of the immediate release formulation.

### Claim 141 (depends on 117)

The solid dosage form composition of claim 117, wherein administration to a subject provides a population geometric mean Tmax between about 4 hours and about 6 hours after administration.

### Claim 142 (depends on 117)

The solid dosage form composition of claim 117, wherein about 27 hours after administration to a subject results in a population average occupancy of dopamine D2 receptors between about 30% and about 50%.

### Claim 143 (depends on 117)

The solid dosage form composition of claim 117, wherein over the period of 12 hours after administration to a subject results in a subject population average maximum QTcF interval prolongation relative to baseline that is less than 10 milliseconds (ms).

### Claim 144 (depends on 117)

The solid dosage form composition of claim 117, wherein the composition comprises about 200 mg of amisulpride by weight of free base.

### Claim 145 (depends on 117)

The solid dosage form composition of claim 117, wherein the composition comprises about 300 mg of amisulpride by weight of free base.

### Claim 146 (depends on 117)

The solid dosage form composition of claim 117, wherein the composition comprises about 400 mg of amisulpride by weight of free base.

### Claim 147 (depends on 117)

The solid dosage form composition of claim 117, comprising
about 200 mg of amisulpride by weight of free base as a solid oral dosage composition, and wherein:
administration of the composition to a subject provides a population geometric mean AUC from 0 to 24 hours after administration (AUC0-24) of amisulpride that is less than about 1900 (ng*h/ml) after administration of a first dose of said solid oral dosage composition.

### Claim 148 (depends on 147)

The solid dosage form composition of claim 147, wherein said administration provides a population geometric mean AUC from 0 to 24 hours after administration (AUC0-24) of amisulpride that is less than about 2500 (ng*h/ml) after one week of administration of said solid oral dosage composition.

### Claim 149 (depends on 117)

The solid dosage form composition of claim 117, comprising
about 400 mg of amisulpride by weight of free base as a solid oral dosage composition, and wherein:
administration of the composition to a subject provides a population geometric mean AUC from 0 to 24 hours after administration (AUC0-24) of amisulpride that is less than about 4400 (ng*h/ml) after administration of a first dose of said solid oral dosage composition.

### Claim 150 (depends on 149)

The solid dosage form composition of claim 149, wherein said administration provides a population geometric mean AUC from 0 to 24 hours after administration (AUC0-24) of amisulpride that is less than about 5400 (ng*h/ml) after one week of administration of said solid oral dosage composition.
